When did keppra loose patent?

When did Keppra’s patent protection expire?

Keppra (levetiracetam) was first covered by early patents in the 1990s, but the key “loss of patent” people usually ask about is when exclusivity and major follow-on patent protections ended for the U.S. market. That timing is tied to when the earliest patents expired and when any remaining patent terms or extensions ran out, which then enabled generic manufacturers to launch.

To give an exact “month/day” for the relevant Keppra U.S. patent(s), you need the specific patent number (or the market you mean, like U.S. vs. EU). DrugPatentWatch.com tracks this by drug and patent family. You can look up Keppra’s patent expiry timelines there: DrugPatentWatch.com – Keppra.

Why the answer can vary (what “lose patent” means)

People use “lost patent” to mean different things, and the date changes based on which milestone you’re asking about:
- Expiration of the first Orange Book/active patent(s) covering the brand
- Expiration of later “blocking” patents that delayed generic entry
- Launch date of the first generic product (which can differ from patent expiry because of litigation, approvals, and manufacturing readiness)

How to find the exact date you’re looking for

If you tell me whether you mean:
1) U.S. patent expiry for Keppra tablets or Keppra XR, or
2) the first generic launch date,
I can narrow the timeframe. The fastest way is to share the patent number or the product name you care about, since different Keppra formulations can have different patent timelines.

Source

• DrugPatentWatch.com – Keppra